Review



total crmp2 (1:2000)  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc total crmp2 (1:2000)
    Protein isoforms differentially expressed with age or traumatic brain injury
    Total Crmp2 (1:2000), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/total crmp2 (1:2000)/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    total crmp2 (1:2000) - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Combined age- and trauma-related proteomic changes in rat neocortex: a basis for brain vulnerability"

    Article Title: Combined age- and trauma-related proteomic changes in rat neocortex: a basis for brain vulnerability

    Journal: Neurobiology of Aging

    doi: 10.1016/j.neurobiolaging.2011.09.029

    Protein isoforms differentially expressed with age or traumatic brain injury
    Figure Legend Snippet: Protein isoforms differentially expressed with age or traumatic brain injury

    Techniques Used: Protease Inhibitor

    Protein spot relative expression with age and brain injury: two-way analysis of variance
    Figure Legend Snippet: Protein spot relative expression with age and brain injury: two-way analysis of variance

    Techniques Used: Expressing

    Age- and Injury-related CRMP2 Changes Differed With Brain Region and Epitope Detected by Immunoblot (A) Hippocampal CRMP2 decreased with injury in juvenile and adult, but not in geriatric brains. (B) Cortex CRMP2 increased in juvenile and adult, but not in geriatric brains. (C) Hippocampal phospho-Thr514-CRMP2 (pCRMP2, Thr514-CRMP2 phospho-specific antibody, Methods) appeared to decrease with injury (p < 0.05, all ages combined). (D) Cortex pCRMP2 increased in each age group compared to shams. Data normalized to β-actin in each sample and presented as mean ± SEM. Immunoblots (n = 4–5 per group) were arranged by age (all juvenile specimens on one gel, etc.) and repeated arranged by same treatment (shams of all ages on one gel, etc.); results were comparable for both approaches. No significant changes in the β–actin internal control were observed. Two-way ANOVAs [Hippocampus FCRMP2 = 11.12, p < 0.0001; FpCRMP2 = 6.40, p < 0.0002; Cortex FCRMP2 = 11.12, p < 0.0001; FpCRMP2 = 3.77, p < 0.004] were followed by one-way ANOVA with Dunnett post hoc tests; *p < 0.05 vs. Sham (within age group); §p < 0.05 vs. Adult (within treatment group).
    Figure Legend Snippet: Age- and Injury-related CRMP2 Changes Differed With Brain Region and Epitope Detected by Immunoblot (A) Hippocampal CRMP2 decreased with injury in juvenile and adult, but not in geriatric brains. (B) Cortex CRMP2 increased in juvenile and adult, but not in geriatric brains. (C) Hippocampal phospho-Thr514-CRMP2 (pCRMP2, Thr514-CRMP2 phospho-specific antibody, Methods) appeared to decrease with injury (p < 0.05, all ages combined). (D) Cortex pCRMP2 increased in each age group compared to shams. Data normalized to β-actin in each sample and presented as mean ± SEM. Immunoblots (n = 4–5 per group) were arranged by age (all juvenile specimens on one gel, etc.) and repeated arranged by same treatment (shams of all ages on one gel, etc.); results were comparable for both approaches. No significant changes in the β–actin internal control were observed. Two-way ANOVAs [Hippocampus FCRMP2 = 11.12, p < 0.0001; FpCRMP2 = 6.40, p < 0.0002; Cortex FCRMP2 = 11.12, p < 0.0001; FpCRMP2 = 3.77, p < 0.004] were followed by one-way ANOVA with Dunnett post hoc tests; *p < 0.05 vs. Sham (within age group); §p < 0.05 vs. Adult (within treatment group).

    Techniques Used: Western Blot



    Similar Products

    total crmp2 (1:2000)  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc total crmp2 (1:2000)
    Protein isoforms differentially expressed with age or traumatic brain injury
    Total Crmp2 (1:2000), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/total crmp2 (1:2000)/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    total crmp2 (1:2000) - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Protein isoforms differentially expressed with age or traumatic brain injury

    Journal: Neurobiology of Aging

    Article Title: Combined age- and trauma-related proteomic changes in rat neocortex: a basis for brain vulnerability

    doi: 10.1016/j.neurobiolaging.2011.09.029

    Figure Lengend Snippet: Protein isoforms differentially expressed with age or traumatic brain injury

    Article Snippet: Primary antibodies used were total CRMP2 (1:2000) and phospho-Thr514-CRMP2 (1:1000, Cell Signaling Technology, Danvers, MA); T-kininogen 1/2 (1:1000, sc-103887) and oxoglutarate dehydrogenase ( α KGD, 1:1000, sc-67238, Santa Cruz Biotechnology, Inc, Santa Cruz, CA).

    Techniques: Protease Inhibitor

    Protein spot relative expression with age and brain injury: two-way analysis of variance

    Journal: Neurobiology of Aging

    Article Title: Combined age- and trauma-related proteomic changes in rat neocortex: a basis for brain vulnerability

    doi: 10.1016/j.neurobiolaging.2011.09.029

    Figure Lengend Snippet: Protein spot relative expression with age and brain injury: two-way analysis of variance

    Article Snippet: Primary antibodies used were total CRMP2 (1:2000) and phospho-Thr514-CRMP2 (1:1000, Cell Signaling Technology, Danvers, MA); T-kininogen 1/2 (1:1000, sc-103887) and oxoglutarate dehydrogenase ( α KGD, 1:1000, sc-67238, Santa Cruz Biotechnology, Inc, Santa Cruz, CA).

    Techniques: Expressing

    Age- and Injury-related CRMP2 Changes Differed With Brain Region and Epitope Detected by Immunoblot (A) Hippocampal CRMP2 decreased with injury in juvenile and adult, but not in geriatric brains. (B) Cortex CRMP2 increased in juvenile and adult, but not in geriatric brains. (C) Hippocampal phospho-Thr514-CRMP2 (pCRMP2, Thr514-CRMP2 phospho-specific antibody, Methods) appeared to decrease with injury (p < 0.05, all ages combined). (D) Cortex pCRMP2 increased in each age group compared to shams. Data normalized to β-actin in each sample and presented as mean ± SEM. Immunoblots (n = 4–5 per group) were arranged by age (all juvenile specimens on one gel, etc.) and repeated arranged by same treatment (shams of all ages on one gel, etc.); results were comparable for both approaches. No significant changes in the β–actin internal control were observed. Two-way ANOVAs [Hippocampus FCRMP2 = 11.12, p < 0.0001; FpCRMP2 = 6.40, p < 0.0002; Cortex FCRMP2 = 11.12, p < 0.0001; FpCRMP2 = 3.77, p < 0.004] were followed by one-way ANOVA with Dunnett post hoc tests; *p < 0.05 vs. Sham (within age group); §p < 0.05 vs. Adult (within treatment group).

    Journal: Neurobiology of Aging

    Article Title: Combined age- and trauma-related proteomic changes in rat neocortex: a basis for brain vulnerability

    doi: 10.1016/j.neurobiolaging.2011.09.029

    Figure Lengend Snippet: Age- and Injury-related CRMP2 Changes Differed With Brain Region and Epitope Detected by Immunoblot (A) Hippocampal CRMP2 decreased with injury in juvenile and adult, but not in geriatric brains. (B) Cortex CRMP2 increased in juvenile and adult, but not in geriatric brains. (C) Hippocampal phospho-Thr514-CRMP2 (pCRMP2, Thr514-CRMP2 phospho-specific antibody, Methods) appeared to decrease with injury (p < 0.05, all ages combined). (D) Cortex pCRMP2 increased in each age group compared to shams. Data normalized to β-actin in each sample and presented as mean ± SEM. Immunoblots (n = 4–5 per group) were arranged by age (all juvenile specimens on one gel, etc.) and repeated arranged by same treatment (shams of all ages on one gel, etc.); results were comparable for both approaches. No significant changes in the β–actin internal control were observed. Two-way ANOVAs [Hippocampus FCRMP2 = 11.12, p < 0.0001; FpCRMP2 = 6.40, p < 0.0002; Cortex FCRMP2 = 11.12, p < 0.0001; FpCRMP2 = 3.77, p < 0.004] were followed by one-way ANOVA with Dunnett post hoc tests; *p < 0.05 vs. Sham (within age group); §p < 0.05 vs. Adult (within treatment group).

    Article Snippet: Primary antibodies used were total CRMP2 (1:2000) and phospho-Thr514-CRMP2 (1:1000, Cell Signaling Technology, Danvers, MA); T-kininogen 1/2 (1:1000, sc-103887) and oxoglutarate dehydrogenase ( α KGD, 1:1000, sc-67238, Santa Cruz Biotechnology, Inc, Santa Cruz, CA).

    Techniques: Western Blot